RUBY Insider Trading Activity and SEC Form 4 Filings
RUBY insider trading summary
No open-market insider purchases or sales of Rubius Therapeutics, Inc. (RUBY) have been reported on SEC Form 4 in the past 12 months.
Latest RUBY insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 24, 2023 | Dannielle Appelhans | CEO and President | Sell | $1K (10,385 @ $0.13) |
| Feb 1, 2023 | Pablo J Cagnoni | Director | Sell | $2K (8,448 @ $0.25) |
| Feb 1, 2023 | Dannielle Appelhans | CEO and President | Sell | $970 (3,878 @ $0.25) |
| Jan 31, 2023 | Laurence A. Turka | Chief Scientific Officer | Sell | $622 (2,593 @ $0.24) |
| Jan 31, 2023 | Pablo J Cagnoni | Director | Sell | $2K (7,240 @ $0.24) |
| Aug 10, 2022 | Dannielle Appelhans | Chief Operating Officer | Sell | $5K (5,737 @ $0.80) |
| Apr 21, 2022 | David R Epstein | Director | Buy | $43K (30,000 @ $1.44) |
| Feb 1, 2022 | Pablo J Cagnoni | CEO and President | Sell | $44K (6,730 @ $6.57) |
| Feb 1, 2022 | Maiken Keson-Brookes | CLO & Corp. Secretary | Sell | $18K (2,732 @ $6.57) |
| Feb 1, 2022 | Laurence A. Turka | Chief Scientific Officer | Sell | $17K (2,517 @ $6.57) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.